Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
about
Beta-thalassemiaHLA-matched sibling bone marrow transplantation for β-thalassemia majorReducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectivesEvaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusionsMRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and PitfallsPregnancy in women with thalassemia: challenges and solutionsmRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overloadDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialEvaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran.Analysis of survival data in thalassemia patients in Shiraz, IranOral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.More pieces to the iron chelation puzzle.Factors affecting health-related quality of life in Thai children with thalassemia.Atherogenesis and iron: from epidemiology to cellular level.Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: A meta-analysis study.Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.Future alternative therapies for β-thalassemia.Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemiaTargeting iron metabolism in drug discovery and deliveryLiver iron content determination by magnetic resonance imaging.The association of ferritin with cardiovascular and all-cause mortality in community-dwellers: The English longitudinal study of ageing.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients.Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia majorPhysiology and pathophysiology of iron cardiomyopathy in thalassemia.Magnetic resonance imaging measurement of iron overload.The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patientsDeferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbilCardiac iron across different transfusion-dependent diseases.Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.Pregnancy Outcomes in Women with Homozygous Beta Thalassaemia: A single-centre experience from OmanSerum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan.Iron chelation therapy in myelodysplastic syndromes.Reassessing the approach to informed consent: the case of unrelated hematopoietic stem cell transplantation in adult thalassemia patientsInternational reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers.Myocardial T2 quantitation in patients with iron overload at 3 Tesla.Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
P2860
Q21202886-9823EB09-484E-4D68-A2F3-134EB25EDA68Q24600037-E0DCEA10-D1B0-4E83-981C-21D5DCEF48BBQ26740347-748753B5-3ED0-4BC5-90EB-2A9D18B560BFQ26765306-8B5C4A48-9A1B-4A48-BD85-F0A20FC79193Q28072173-E3A85CAA-53EA-4E6F-850E-C47519D78CE5Q28080216-0FA2BE9A-79FE-4826-892D-AA12B55662E5Q28384189-141BE951-E9AA-45F8-B08C-20378FA314EBQ28552171-3CB84872-0D51-4A98-8624-CC25CB51BD64Q30401570-8AE4A369-A1E7-4691-9DDD-0BD2B1AB2651Q30982741-EB1C1635-106C-4EB4-ABE5-96AD9F7A13BFQ31037298-0E795829-A8B4-4CF0-B71C-D1F3C3DB496CQ33349435-022B58A1-403B-4E6B-B1A9-E8BC1069B917Q33533903-B0CAA5BB-9563-4902-B758-9B09E74C8D71Q33595279-56B81271-15E7-48D4-881F-802FB4E8D165Q33624121-A9AFF80C-9576-496E-A6BF-895FCA1EF408Q33629906-2E58B416-0D40-4C9D-AE17-8AD12012EA8DQ33647638-1FF8724B-5DFF-4A97-9B8C-12D42E321397Q33659678-8B33372A-C903-4E0E-B3AB-CD30266BC721Q33670385-517EEACF-C0B4-4489-8CCB-6921988F651EQ33729649-C3E94D3A-5179-4D49-872F-5CBB6B75DC29Q33757232-D62A2291-67F8-4872-B96B-BE445A550A4AQ33764777-6CA9355A-A447-4131-8BC7-1A5707A2F3CFQ33773169-9A919DC5-3EF7-404A-9D36-E3B83C4B1C44Q33801826-F2469A22-F71E-475A-B39C-9C5C3781D6F5Q33840284-8D825A77-6A03-4B7F-AFC0-39E9DDC8EE1BQ33843186-D27A1791-27AF-4C10-888E-07402059C9E8Q33920971-97246873-4DC3-4E7C-AF47-5CAF07318436Q33944096-C98E0E49-A7B3-4686-9B2F-2B1A3FBCF54CQ33944366-0FD77F88-659A-4F80-8971-B433AC520FA5Q33955451-3053243E-BB05-458E-B123-347FF501130DQ33958533-0536EFE7-D0CB-4C51-8411-71CEB87129EDQ33958560-922E2F8D-507F-4A8C-8B1E-2C92307D9764Q33978886-57519E4F-8565-4647-8FDA-FB8A87B3C82FQ33982929-CCA7E406-A104-40DF-80FC-E39EAA233533Q33990879-D8EA477E-D0B4-4CE8-AEF9-E1573A796F48Q34002840-0DEC0053-BC38-4B4B-9B49-7B193999B7F5Q34060932-518E5984-8D01-443F-8A16-1714CFA19E8EQ34158260-AF860428-D86D-4C38-825B-B385E1CAC24DQ34160289-3EF665BE-BD25-45CB-8B8E-5ECDED37ABC6Q34269245-6003645C-1118-403F-A90E-87A52AC53CEE
P2860
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Survival and complications in ...... transfusion and deferoxamine.
@en
Survival and complications in ...... transfusion and deferoxamine.
@nl
type
label
Survival and complications in ...... transfusion and deferoxamine.
@en
Survival and complications in ...... transfusion and deferoxamine.
@nl
prefLabel
Survival and complications in ...... transfusion and deferoxamine.
@en
Survival and complications in ...... transfusion and deferoxamine.
@nl
P2093
P1433
P1476
Survival and complications in ...... transfusion and deferoxamine.
@en
P2093
Antonio Piga
Avital Cnaan
Caterina Borgna-Pignatti
Gian Luca Forni
Giovanni Carlo Del Vecchio
Huaqing Zhao
Maria Antonietta Romeo
Maria Domenica Cappellini
Maria Rita Gamberini
Piero De Stefano
P304
P577
2004-10-01T00:00:00Z